Image

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Study testing SAR443579 for certain relapsed or hard-to-treat blood cancers.

Recruiting
1 years and older
All
Phase 1/2
  • Simplified description (AI rewritten)
  • Technical description (Original)
In this study, researchers are testing a new treatment called **SAR443579** in people with certain types of blood cancer. These cancers include **Acute Myeloid Leukemia (AML)**, **B-cell Acute Lymphoblastic Leukemia (B-ALL)**, **High Risk Myelodysplasia (HR-MDS)**, and **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)**. **Acute Myeloid Leukemia (AML)** is a type of cancer where the blood cells are abnormal and grow uncontrollably. **B-cell Acute Lymphoblastic Leukemia (B-ALL)** is a type of leukemia that affects white blood cells. **High Risk Myelodysplasia (HR-MDS)** is a condition where the bone marrow doesn't make enough healthy blood cells. **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)** is a rare cancer that affects blood cells. The study will last for 2.5 years for each participant. To join, participants must be at least 1 year old (2 years in France) and meet specific medical criteria. **Key Points:** - **Study Duration**: 2.5 years for each participant. - **Eligibility**: Must be at least 1 year old (2 years in France) with specific medical criteria. - **Visits and Tests**: Includes regular doctor visits and medical tests. This study aims to find out if SAR443579 is safe and helps fight these cancers.
Print
Study details
    Acute Lymphocytic Leukaemia
    Acute Myeloid Leukaemia Refractory
    Myelodysplastic Syndromes
    Blastic Plasmacytoid Dendritic Cell Neoplasia

NCT05086315

Sanofi

31 March 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.